The $56 million bet that jumping genes can fix CAR-T’s weakest link
Typewriter emerged from stealth with a $56M Series A to commercialize retrotransposon-based whole-gene insertion, targeting in vivo CAR-T and genetic liver disease. Non-human primate data arrives late 2026.